A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (T-BRAIN)

Description

Patients with small cell lung cancer (SCLC) have a high risk of brain metastases (BM). After progression on first line systemic therapy, second line treatment has limited intracranial efficacy, leading to the need for new systemic therapies with efficacy both systemically and intracranially.

Tarlatamab is a bispecific T-cell engager targeting delta-like ligand 3 (DLL3) and CD3 and has shown promising activity in heavily pretreated patients with SCLC.

The T-BRAIN study is a single-arm, phase 2 study evaluating the intracranial efficacy of tarlatamab in patients with SCLC and asymptomatic untreated or progressive brain metastases after first line chemotherapy.

Who is the principal investigator?

Prof. dr. Lizza Hendriks

Team

Drs. Maud Salmans
Dr. Sander Croes
Dr. Robin van Geel

Who is collaborating?

Antoni van Leeuwenhoek hospital
Erasmus MC
University Medical Centre Groningen

Contact for general questions

Drs. Maud Salmans (maud.salmans@mumc.nl)
Also, visit our Vacancies page.

Was this page useful?

Good

Sufficient

Insufficient

To help us improve our website we would like to know why you do not find this page useful. You can select more than one reason below and give your opinion.

I find the page too difficult to understand

I can\'t find what I am looking for

I find that the page is too boring

Other reason (fill in below)

Your opinion

Geef uw mening over de website, of vertel ons hoe wij onze website kunnen verbeteren.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.